Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gemmell, C. G.
Right arrow Articles by participating investigators in France, Germany, Holland, Spain, Italy, Sweden and the UK, o. b. o.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gemmell, C. G.
Right arrow Articles by participating investigators in France, Germany, Holland, Spain, Italy, Sweden and the UK, o. b. o.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 47-52
© 2001 The British Society for Antimicrobial Chemotherapy

Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison

Curtis G. Gemmella,* and on behalf of participating investigators in France, Germany, Holland, Spain, Italy, Sweden and the UK{dagger}

a Department of Bacteriology, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK

Using standardized in vitro susceptibility tests, 3382 bacteria recently isolated from skin, blood or respiratory tract infections were analysed for their susceptibility to linezolid, a new oxazolidinone, and a number of comparator antibacterial agents. Isolates originated in France, Italy, Germany, Spain, Sweden, The Netherlands and the UK. Laboratories in each country independently conducted broth microdilution susceptibility tests using NCCLS methods and epsilonometry (Etest). Isolates of Gram-positive cocci tested in each laboratory included methicillin-susceptible and -resistant Staphylococcus aureus, methicillin-susceptible and -resistant Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae and Enterococcus spp. Isolates of Moraxella catarrhalis and Haemophilus influenzae were also included. Where appropriate, comparator drugs (oxacillin, vancomycin, gentamicin, co-amoxiclav, ciprofloxacin, erythromycin, penicillin G, clindamycin and ampicillin) were also tested. Linezolid demonstrated excellent activity against all of the Gram-positive cocci with MIC50s ranging from 0.5 to 4 mg/L. The drug demonstrated only modest activity against M. catarrhalis and H. influenzae with MIC50s ranging from 4 to 16 mg/L.

* Tel: +44-141-211-4654; Fax: +44-141-552-1524; E-mail: c.g.gemmell{at}clinmed.gla.ac.uk

{dagger} The participating investigators are listed in the Acknowledgements.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
F. C. Tenover, P. P. Williams, S. Stocker, A. Thompson, L. A. Clark, B. Limbago, R. B. Carey, S. M. Poppe, D. Shinabarger, and J. E. McGowan Jr.
Accuracy of Six Antimicrobial Susceptibility Methods for Testing Linezolid against Staphylococci and Enterococci
J. Clin. Microbiol., September 1, 2007; 45(9): 2917 - 2922.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
A. Van Griethuysen, A. Van 't Veen, A. Buiting, T. Walsh, and J. Kluytmans
High Percentage of Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Glycopeptides in The Netherlands
J. Clin. Microbiol., June 1, 2003; 41(6): 2487 - 2491.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. M. Bell, J. D. Turnidge, C. H. Ballow, R. N. Jones, and the ZAPS Regional Participants
Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific
J. Antimicrob. Chemother., February 1, 2003; 51(2): 339 - 345.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. R. Anderegg, D. J. Biedenbach, and R. N. Jones
In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2662 - 2664.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. E. Low, J. de Azavedo, K. Weiss, T. Mazzulli, M. Kuhn, D. Church, K. Forward, G. Zhanel, A. Simor, and A. McGeer
Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000
Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1295 - 1301.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Villani, M. B. Regazzi, F. Marubbi, P. Viale, L. Pagani, F. Cristini, B. Cadeo, G. Carosi, and R. Bergomi
Cerebrospinal Fluid Linezolid Concentrations in Postneurosurgical Central Nervous System Infections
Antimicrob. Agents Chemother., March 1, 2002; 46(3): 936 - 937.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.